1. Home
  2. VGAS vs SKYE Comparison

VGAS vs SKYE Comparison

Compare VGAS & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Verde Clean Fuels Inc.

VGAS

Verde Clean Fuels Inc.

HOLD

Current Price

$1.84

Market Cap

50.5M

Sector

Industrials

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.66

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VGAS
SKYE
Founded
2007
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.5M
44.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
VGAS
SKYE
Price
$1.84
$0.66
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$14.75
AVG Volume (30 Days)
38.5K
285.7K
Earning Date
03-27-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$0.64
52 Week High
$4.08
$5.75

Technical Indicators

Market Signals
Indicator
VGAS
SKYE
Relative Strength Index (RSI) 57.78 39.87
Support Level $1.20 N/A
Resistance Level $3.29 $0.83
Average True Range (ATR) 0.17 0.05
MACD 0.06 -0.00
Stochastic Oscillator 65.93 11.08

Price Performance

Historical Comparison
VGAS
SKYE

About VGAS Verde Clean Fuels Inc.

Verde Clean Fuels Inc is a renewable energy company specializing in the conversion of synthesis gas, or syngas, derived from diverse feedstocks, such as biomass, MSW, and mixed plastics, as well as natural gas (including synthetic natural gas) and other feedstocks, into liquid hydrocarbons that can be used as gasoline through a proprietary liquid fuels technology, the STG process.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: